Mouhammed Habra
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mouhammed Habra as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:45 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05634577 · A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical CarcinomaM.D. Anderson Cancer Center · terminated · Adrenocortical Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:45 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:45 UTC. The ranking covers the 200 most relevant of 15 PubMed records, and a shared surname and initials can bring in a namesake. All 15 on PubMed
- Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.N Engl J Med · 20151,588 citationsRCR 53.1
- Elevated depression symptoms predict long-term cardiovascular mortality in patients with atrial fibrillation and heart failure.Circulation · 2009178 citationsRCR 5.6
- 145 citationsRCR 5.1
- Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.J Immunother Cancer · 2019131 citationsRCR 5.2
- Phase 2 study of pembrolizumab in patients with advanced rare cancers.J Immunother Cancer · 2020123 citationsRCR 5.7
- Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma.Br J Cancer · 2013103 citationsRCR 3.1
- 95 citationsRCR 3.5
- Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid.Eur J Cancer · 201770 citationsRCR 2.5
- A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma.Invest New Drugs · 202057 citationsRCR 2.6
- 38 citationsRCR 2.7